Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
195 hedge funds and large institutions have $2.11B invested in Impax Laboratories, Inc. in 2016 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 84 increasing their positions, 56 reducing their positions, and 28 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 56
7% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 28
1% less funds holding
Funds holding: 196 → 195 (-1)
8% less call options, than puts
Call options by funds: $2.31M | Put options by funds: $2.52M
2.32% less ownership
Funds ownership: 91.61% → 89.29% (-2.3%)
26% less capital invested
Capital invested by funds: $2.84B → $2.11B (-$734M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$25.6M |
| 2 |
GAM
Gotham Asset Management
New York
|
+$16.1M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$14.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$28.2M |
| 2 |
BP
Banbury Partners
Charlotte,
North Carolina
|
-$20.5M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$17.4M |
| 4 |
PC
PointState Capital
New York
|
-$12.8M |
| 5 |
BJCM
Blue Jay Capital Management
Los Angeles,
California
|
-$12.6M |
IPXL Hedge Fund Activity: Q1 2016 in Review
195 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q1 2016, worth a combined $2.11B — down 26% from $2.84B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IPXL positions and 28 closed out — a net gain of 2 holders — while 84 added to existing stakes and 56 trimmed.
The largest buyer was GW&K Investment Management, adding an estimated $25.6M. The largest seller was Morgan Stanley, cutting an estimated $28.2M.
- 195 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q1 2016, down from 196 in Q4 2015.
- Funds reported $2.11B of Impax Laboratories, Inc. stock for Q1 2016, down 26% quarter-over-quarter.
- 30 funds opened new Impax Laboratories, Inc. positions in Q1 2016 and 28 closed out, a net change of +2 holders.
- The largest Impax Laboratories, Inc. buyer in Q1 2016 was GW&K Investment Management, an estimated $25.6M added.
- The largest Impax Laboratories, Inc. seller in Q1 2016 was Morgan Stanley, an estimated $28.2M sold.
Based on aggregated 13F filings for Q1 2016.